Research Topics
Species | David PreissSummaryCountry: UK Publications
| Collaborators
|
Detail Information
Publications
Statins and the risk of new-onset diabetes: a review of recent evidenceDavid Preiss
BHF Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow, Scotland, UK
Curr Opin Lipidol 22:460-6. 2011..We discuss the relevant data including newly published results, which demonstrate a dose-dependent association, we place these findings in clinical context and we consider clinical implications...- Lipid-modifying therapies and risk of pancreatitis: a meta-analysisDavid Preiss
BHF Glasgow Cardiovascular Research Centre, University of Glasgow, 126 University Pl, Glasgow G12 8TA, United Kingdom
JAMA 308:804-11. 2012..Although lipid guidelines recommend fibrate therapy to reduce pancreatitis risk in persons with hypertriglyceridemia, fibrates may lead to the development of gallstones, a risk factor for pancreatitis... - Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysisDavid Preiss
BHF Glasgow Cardiovascular Research Centre, University of Glasgow, 126 University Pl, Glasgow G12 8TA, Scotland, United Kingdom
JAMA 305:2556-64. 2011..A recent meta-analysis demonstrated that statin therapy is associated with excess risk of developing diabetes mellitus... - A systematic review of event rates in clinical trials in diabetes mellitus: the importance of quantifying baseline cardiovascular disease history and proteinuria and implications for clinical trial designDavid Preiss
BHF Cardiovascular Research Centre, University of Glasgow, Glasgow, United Kingdom
Am Heart J 161:210-219.e1. 2011.... - The inverse relationship between alanine aminotransferase in the normal range and adverse cardiovascular and non-cardiovascular outcomesIan Ford
From the Robertson Centre for Biostatistics, University of Glasgow, Glasgow, Scotland
Int J Epidemiol 40:1530-8. 2011..High serum alanine aminotransferase (ALT) levels have been associated with increased risk of diabetes and with increased mortality, but associations of variations of ALT in the normal range with outcomes have been less well studied... - Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trialsNaveed Sattar
British Heart Foundation Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow, UK
Lancet 375:735-42. 2010..We aimed to establish by a meta-analysis of published and unpublished data whether any relation exists between statin use and development of diabetes... - Fasting plasma glucose in non-diabetic participants and the risk for incident cardiovascular events, diabetes, and mortality: results from WOSCOPS 15-year follow-upDavid Preiss
Faculty of Medicine, University of Glasgow, Glasgow, UK
Eur Heart J 31:1230-6. 2010..The evidence base for fasting plasma glucose (FPG) in the non-diabetic range as a risk factor for cardiovascular disease (CVD) is inconclusive. We investigated this question in the West of Scotland Coronary Prevention Study (WOSCOPS)... - Eplerenone and new-onset diabetes in patients with mild heart failure: results from the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF)David Preiss
British Heart Foundation Cardiovascular Research Centre, University of Glasgow, Glasgow G12 8TA, UK
Eur J Heart Fail 14:909-15. 2012..In addition, though the combination of diabetes and chronic heart failure (CHF) carries a poor prognosis, few studies have examined predictors of new-onset diabetes in those with CHF... - Liver enzymes, nonalcoholic fatty liver disease, and incident cardiovascular disease: a narrative review and clinical perspective of prospective dataNazim Ghouri
BHF Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow, UK
Hepatology 52:1156-61. 2010..The presence of NAFLD should be a clear indication for diabetes screening, but cardiovascular risk screening should be performed with the use of existing risk calculators and should be guided by established cardiovascular risk factors... - Lipids, lipid modifying agents and cardiovascular risk: a review of the evidenceDavid Preiss
BHF Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow, UK
Clin Endocrinol (Oxf) 70:815-28. 2009..Ongoing studies such as ACCORD, IMPROVE-IT, ASCEND, ORIGIN and HPS2-THRIVE should assist in answering outstanding questions over the next 5 years... 
Predictors of development of diabetes in patients with chronic heart failure in the Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM) programDavid Preiss
BHF Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow, Scotland, UK
Diabetes Care 32:915-20. 2009....- Non-alcoholic fatty liver disease: an overview of prevalence, diagnosis, pathogenesis and treatment considerationsDavid Preiss
British Heart Foundation, Glasgow Cardiovascular Research Centre, University of Glasgow, 126 University Place, Glasgow G12 8TA, Scotland, UK
Clin Sci (Lond) 115:141-50. 2008..Furthermore, the cost/benefit ratio of any new therapies, and any potential harms, must be evaluated carefully before being clinically advocated...